Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome | Zendy

Sagar S. Patel | Zendy; Lisa Rybicki | Zendy; Brad Pohlman | Zendy; Brian J. Bolwell | Zendy; Aaron T. Gerds | Zendy; Betty K. Hamilton | Zendy; Rabi Hanna | Zendy; Matt Kalaycio | Zendy; Navneet S. Majhail | Zendy; Ronald Sobecks | Zendy

Open Access

Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome

Author(s) -

Sagar S. Patel,

Lisa Rybicki,

Brad Pohlman,

Brian J. Bolwell,

Aaron T. Gerds,

Betty K. Hamilton,

Rabi Hanna,

Matt Kalaycio,

Navneet S. Majhail,

Ronald Sobecks

Publication year - 2019

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2019.09.002

Subject(s) - busulfan , fludarabine , medicine , myeloid leukemia , myelodysplastic syndromes , cyclophosphamide , hematopoietic cell , hematopoietic stem cell transplantation , transplantation , oncology , haematopoiesis , chemotherapy , stem cell , biology , bone marrow , genetics

Busulfan/cyclophosphamide (Bu/Cy) and busulfan/fludarabine (Bu/Flu) are both standard myeloablative conditioning (MAC) regimens for allogeneic hematopoietic cell transplantation (alloHCT). We compared the effectiveness of these regimens with a focus on quality of life (QOL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research